Jan 28, 2020   SOURCE: PR NewsWire

ROI in Pharmaceutical R&D: An Assessment of ROI in R&D by Leading Pharmaceutical Companies in the Industry

DUBLIN, Jan. 28, 2020 /PRNewswire/ -- The "ROI in Pharmaceutical R&D: How to Halt the Decline" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The "ROI in Pharmaceutical R&D" study begins with the challenges facing biotech and pharmaceutical companies today. It goes on to discuss regulatory approval processes in various countries, how these are changing, and the knock-on effects which the pharma/biotech companies will have to address. The report reviews several key financial ratios and discusses how to maximize clinical development success rate. It looks at how machine learning (ML) and artificial intelligence (AI), along with Big Data, are disrupting the pharma/biotech industry, in a positive way. The report then reviews the global markets for treatments for selected cancers, chronic diseases, cardiovascular disease, neurological diseases, infectious diseases and rare diseases.

It includes a discussion on how companies need to deeply integrate ML, AI and Big Data into drug discovery and clinical testing - or risk falling behind the competition. The report wraps up with summaries of selected companies active in these spaces and beginning to utilize digital tools in R&D.

Key report features:

    --  49 data tables and 30 additional tables
    --  An assessment of return on investment (ROI) in R&D by top pharmaceutical
        companies within the industry
    --  Analyses of the global market trends for various chronic disease areas,
        with data from 2016 to 2017, and projections of compound annual growth
        rates (CAGRs) through 2024
    --  Pipeline analysis of various therapeutic drugs with oncology being the
        largest, and coverage of ongoing clinical trials and promising
        forthcoming therapies in late stage etc.
    --  Outlining details of many factors involved in calculating ROI in R&D in
        pharma and how some of those factors are adjusted/developed to improve
        R&D ROI
    --  Discussion of the competitive landscape and key mergers and acquisition
        deals, partnerships, collaborations during the timeframe, 2014-2024
    --  Profile descriptions of top 15 pharmaceutical companies, their sales
        data, market capitalization and areas of R&D etc., including 23andMe,
        AstraZeneca PLC, Celgene Corp., Eli Lilly and Co., GlaxoSmithKline PLC,
        Merck & Co. Inc., Pfizer Inc. and Sanofi

Key Topics Covered:


Company Profiles

    --  Challenges Facing Pharma and Biotech Companies
    --  Regulatory Overview and New Drug Approvals
    --  Key Financial Ratios for Pharma and Biotech Companies
    --  Maximizing Clinical Development Success Rates
    --  The Advantages of Being - or Acting - Small
    --  The Digital Transformation of Biopharma Companies
    --  Leveraging Open Innovation to Solve Development Challenges
    --  The Global Pharma and Biotech Market for Oncology
    --  The Global Pharma and Biotech Market for Chronic Diseases
    --  The Global Pharma and Biotech Market for Cardiovascular Disease
    --  The Global Pharma and Biotech Market for Neurological Diseases
    --  The Global Pharma and Biotech Market for Infectious Diseases
    --  The Global Pharma and Biotech Market for Rare Diseases
    --  The Changing Future of Biopharma Work

    --  23Andme
    --  Abbvie
    --  Allergan Plc
    --  Amgen Inc.
    --  Astellas Pharma Inc.
    --  Astrazeneca Plc
    --  Bayer Ag
    --  Biogen Idec
    --  Boehringer Ingelheim Gmbh
    --  Bristol-Myers Squibb Co.
    --  Celgene Corp.
    --  CSL Behring
    --  Eli Lilly And Co.
    --  Exscientia
    --  Gilead Sciences Inc.
    --  Glaxosmithkline Plc
    --  Johnson & Johnson Inc.
    --  Merck & Co., Inc.
    --  Novartis Ag
    --  Novo Nordisk A/S
    --  Numerate Inc.
    --  Pfizer Inc.
    --  Roche (F. Hoffman-La Roche Ag)
    --  Sanofi
    --  Vertex Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/1hpicf

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/roi-in-pharmaceutical-rd-an-assessment-of-roi-in-rd-by-leading-pharmaceutical-companies-in-the-industry-300994442.html

SOURCE Research and Markets